In addition, they act as dominant-negative competitors for DNA binding and/or heteroduplex formation with p53 and wild-type TAp73, and confer drug resistance to tumor cells harbouring wild-type p53 and/or TAp73 [2,3]. The gene discussed is TP53; the disease is neoplasm.